Our Technology:
BMProbe™

One wire, multiple indications

The BMProbe™ is a platform technology based on a minimally invasive device which can be configured to capture specific cells directly from the peripheral venous blood stream. The antibody is the central component of the BMProbe™, providing the basis of analyte selection and detection, like an ELISA.

Coated with antibodies specific to circulating endothelial cells, the BMProbe™ can be used to personalize patient treatment in cardiology. When antibodies are applied to target circulating tumor cells, the BMProbe™ can be used to detect cancer very early. More applications are also possible.

All HaimaChek™ products are subject to FDA clearance.

1

Insertion

The BMProbe is inserted into the peripheral venous system. Often, the present indwelling cannula (G18 or larger) can be used avoiding further punctures of the vein.
2

Incubation

During a 30 mins application, more than one liter of blood flows through the punctured vein. The BMProbe’s geometry causes optimal conditions for cell adhesion to maximize the number of cells to be isolated.
3

Downstream analysis

Once the BMProbe™ is withdrawn, the isolated cells are counted and analyzed to deliver a result that physicians can use to personalize patient treatment.

Our fields of activity

Cardiology

Heart infarction, covid-19, diabetes, and heart failure all cause the level of circulating endothelial cells to increase in the bloodstream. This biomarker has the potential to personalize the treatment of millions of patients.

Learn more about Cardiology

Oncology

Current technologies are not sufficient to detect early primary tumors or metastases. This inhibits a physician’s ability to determine the optimal treatment course in many situations.

Learn more about Oncology
2017-2021 © Copyright by HaimaChek™ Inc. All rights reserved. Imprint & Privacy Policy